<DOC>
	<DOCNO>NCT03088930</DOCNO>
	<brief_summary>This study evaluate efficacy crizotinib induction therapy participant surgically resectable ALK rearrangement , ROS1 rearrangement , MET exon 14 mutation positive NSCLC .</brief_summary>
	<brief_title>Evaluating Crizotinib Neoadjuvant Setting Patients With Non-small Cell Lung Cancer</brief_title>
	<detailed_description>Participants stage IA-IIIA , surgically resectable lung adenocarcinoma activate alteration ALK , ROS1 MET receive neoadjuvant treatment crizotinib . This neoadjuvant treatment last 6 week last day dose crizotinib , participant undergo surgical resection , follow 5 year follow-up via chart review .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>1 . Histologically confirm stage IAIIIA NSCLC deem surgically resectable board certify thoracic surgeon . 2 . Staging PETCT scan MRI brain show evidence metastatic disease ( mediastinoscopy require unless image indeterminate consider standard care ) 3 . Documented evidence ALK rearrangement ( FISH , IHC , NGS ) , ROS1 rearrangement ( FISH NGS ) , MET oncogene define MET exon 14 skipping ( NGS ) , MET Y1003X mutation MET gene fusion ( NGS ) NSCLC tumor specimen CLIAapproved laboratory . 4 . Measurable disease define RECIST 1.1 criterion . 5 . Life expectancy least 24 month . 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 7 . Age ≥ 18 year 8 . Have normal QT interval ECG evaluation QT correct Fridericia ( QTcF ) ≤ 450 m male ≤ 470 m female 9 . Adequate organ function : Absolute neutrophil count ( ANC ) ≥1500/µL Platelets ≥75,000/µL Hemoglobin ≥ 10g/dL AST /ALT ≤ 2.5 x upper limit normal ( ULN ) Total serum bilirubin ≤ 1.5 x ULN Serum creatinine ≤ 1.5 x UNL Serum amylase/lipase ≤ 1.5 x UNL 10 . Negative serum pregnancy test within 7 day D1 treatment woman child bear potential . 11 . If fertile , willing use highly effective form contraception ( define combination least two follow method : condom barrier method , oral contraceptive , implantable contraceptive , intrauterine device ) dose period least 4 month dose period . 12 . Ability provide sign informed consent willing able comply study requirement . 1 . Stage IIIB IV NSCLC . 2 . History presence pulmonary interstitial disease , drugrelated pneumonitis . 3 . Malabsorption syndrome GI illness could affect oral absorption study drug 4 . Inability swallow oral medication 5 . Have significant , uncontrolled active cardiovascular disease , specifically include restrict : Myocardial infarction ( MI ) within 6 month trial enrollment Unstable angina within 6 month trial enrollment Congestive heart failure ( CHF ) 6 month prior trial enrollment Any history ventricular arrhythmia Cerebrovascular accident transient ischemic attack within 6 month D1 treatment Clinically significant atrial arrhythmia severe baseline bradycardia define rest heart rate &lt; 50 beat per minute Uncontrolled hypertension define baseline SBP &gt; 160 DBP &gt; 100 3 separate clinic visit past history hypertensive urgency , emergency encephalopathy 6 . Have active infection require antibiotic 7 . Pregnant lactate female . 8 . Prior treatment ALK , ROS1 MET inhibitor 9 . Any prior anticancer therapy diagnosis 10 . Any active cancer diagnosis ( basal squamous cell cancer allow ) within last 5 year patient receive active therapy untreated . Any cancer diagnosis within last 5 year consider `` treated '' and/ surveillance may include trial . 11 . Have condition illness , opinion investigator would compromise patient safety interfere evaluation study drug ( include limit HIV HCV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>